Meeting
2017 ASCO Annual Meeting
Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.
Authors
Michael Teufel
Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Michael Teufel , Karl Köchert , Gerold Meinhardt , Jordi Bruix
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01774344
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4078)
DOI
10.1200/JCO.2017.35.15_suppl.4078
Abstract #
4078
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley
Poster
2018 Gastrointestinal Cancers Symposium
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
First Author: Jordi Bruix
Poster
2017 Gastrointestinal Cancers Symposium
Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: Masafumi Ikeda
Poster
2014 ASCO Annual Meeting
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
First Author: Jordi Bruix